Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David J Pinato

Showing results (141-150 of 238) with videos related to

Pageof 24
Sort By:
Liver Cancer|October 12, 2019
Stereotactic Body Radiation Therapy as an Alternative Treatment for Patients with Hepatocellular Carcinoma Compared to Sorafenib: A Propensity Score AnalysisDominik Bettinger, David J Pinato, Michael Schultheiss, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 17, 2024
Circulating Tumor DNA Dynamics and Clinical Outcome in Metastatic Colorectal Cancer Patients Undergoing Front-Line ChemotherapyMichele Ghidini, Jens Claus Hahne, Chiara Senti, et al.
JAMA Oncology|December 26, 2024
Deep Learning Model for Predicting Immunotherapy Response in Advanced Non-Small Cell Lung CancerMehrdad Rakaee, Masoud Tafavvoghi, Biagio Ricciuti, et al.
Journal for Immunotherapy of Cancer|October 18, 2023
Increased interleukin-6/C-reactive protein levels are associated with the upregulation of the adenosine pathway and serve as potential markers of therapeutic resistance to immune checkpoint inhibitor-based therapies in non-small cell lung cancerAbdul Rafeh Naqash, Justin D McCallen, Emma Mi, et al.
Journal for Immunotherapy of Cancer|October 8, 2020
Impact of corticosteroid therapy on the outcomes of hepatocellular carcinoma treated with immune checkpoint inhibitor therapyDavid J Pinato, Ahmed Kaseb, Yinghong Wang, et al.
Lung Cancer (Amsterdam, Netherlands)|February 22, 2023
Second-line treatment outcomes after progression from first-line chemotherapy plus immunotherapy in patients with advanced non-small cell lung cancerEdouard Auclin, Jose Benitez-Montanez, Marco Tagliamento, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 5, 2024
Safety and Preliminary Efficacy of Pembrolizumab Following Transarterial Chemoembolization for Hepatocellular Carcinoma: The PETAL Phase Ib StudyDavid J Pinato, Antonio D'Alessio, Claudia Angela Maria Fulgenzi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 27, 2026
Phase I Study of Mosperafenib, a Novel Paradox Breaker B-Raf Proto-Oncogene Serine/Threonine Kinase (BRAF) Inhibitor, in Patients With <i>BRAF</i> V600-Mutant Solid TumorsMaria Vieito, Elisa Fontana, Catherine H Han, et al.
JAMA Network Open|June 4, 2025
Immune Checkpoint Inhibitors for Patients With Preexisting Autoimmune Neurologic DisordersKylie Fletcher, Marc Machaalani, Razane El Hajj Chehade, et al.
Cambridge Prisms. Precision Medicine|February 13, 2025
UK cancer vaccine advance - Recognising and realising opportunitiesCharles Craddock, Philip Earwaker, Matthew Fittall, et al.
Pageof 24

Showing results (141-150 of 238) with videos related to

Sort By:
Pageof 24
Liver Cancer|October 12, 2019
Stereotactic Body Radiation Therapy as an Alternative Treatment for Patients with Hepatocellular Carcinoma Compared to Sorafenib: A Propensity Score AnalysisDominik Bettinger, David J Pinato, Michael Schultheiss, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 17, 2024
Circulating Tumor DNA Dynamics and Clinical Outcome in Metastatic Colorectal Cancer Patients Undergoing Front-Line ChemotherapyMichele Ghidini, Jens Claus Hahne, Chiara Senti, et al.
JAMA Oncology|December 26, 2024
Deep Learning Model for Predicting Immunotherapy Response in Advanced Non-Small Cell Lung CancerMehrdad Rakaee, Masoud Tafavvoghi, Biagio Ricciuti, et al.
Journal for Immunotherapy of Cancer|October 18, 2023
Increased interleukin-6/C-reactive protein levels are associated with the upregulation of the adenosine pathway and serve as potential markers of therapeutic resistance to immune checkpoint inhibitor-based therapies in non-small cell lung cancerAbdul Rafeh Naqash, Justin D McCallen, Emma Mi, et al.
Journal for Immunotherapy of Cancer|October 8, 2020
Impact of corticosteroid therapy on the outcomes of hepatocellular carcinoma treated with immune checkpoint inhibitor therapyDavid J Pinato, Ahmed Kaseb, Yinghong Wang, et al.
Lung Cancer (Amsterdam, Netherlands)|February 22, 2023
Second-line treatment outcomes after progression from first-line chemotherapy plus immunotherapy in patients with advanced non-small cell lung cancerEdouard Auclin, Jose Benitez-Montanez, Marco Tagliamento, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 5, 2024
Safety and Preliminary Efficacy of Pembrolizumab Following Transarterial Chemoembolization for Hepatocellular Carcinoma: The PETAL Phase Ib StudyDavid J Pinato, Antonio D'Alessio, Claudia Angela Maria Fulgenzi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 27, 2026
Phase I Study of Mosperafenib, a Novel Paradox Breaker B-Raf Proto-Oncogene Serine/Threonine Kinase (BRAF) Inhibitor, in Patients With <i>BRAF</i> V600-Mutant Solid TumorsMaria Vieito, Elisa Fontana, Catherine H Han, et al.
JAMA Network Open|June 4, 2025
Immune Checkpoint Inhibitors for Patients With Preexisting Autoimmune Neurologic DisordersKylie Fletcher, Marc Machaalani, Razane El Hajj Chehade, et al.
Cambridge Prisms. Precision Medicine|February 13, 2025
UK cancer vaccine advance - Recognising and realising opportunitiesCharles Craddock, Philip Earwaker, Matthew Fittall, et al.
Pageof 24